Logos Global Management LP

Hedge Fund • Long/Short

Logos Global Management LP is a Long/Short Hedge Fund based in San Francisco, CA led by Graham Gordon Walmsley, reporting $1.4B in AUM as of Q3 2025 with 86% Healthcare concentration.

Managing PartnerGraham Gordon Walmsley

Portfolio Value: $987.5M
Positions: 51
Top Holding: RVMD at 8.28%
Last Reported: Q3 2025

Address1 Letterman Drive, Bldg C, Ste C3-350, San Francisco, CA, 94129, United States

Top Holdings

Largest long holdings in Logos Global Management LP's portfolio (46.3% of total portfolio)

See all holdings

GthenH

Holding	Sector	Position	Weight	Traded	Ownership	Owned Since
1 Revolution Medicines, Inc. RVMD	Biotechnology Healthcare	$81.7M	8.28%	+$2.3M Bought	0.94% 1.8M shares	Q3 2023 Held for 2y 2m
2 IDEAYA Biosciences, Inc. IDYA	Biotechnology Healthcare	$61.2M	6.20%	-$29.8M Sold	2.57% 2.3M shares	Q3 2021 Held for 4y 2m
3 Akero Therapeutics AKRO	Biotechnology Healthcare	$57.0M	5.77%	—	1.50% 1.2M shares	Q3 2022 Held for 3y 2m
4 Arvinas ARVN	Biotechnology Healthcare	$47.5M	4.81%	+$19.4M Bought	7.59% 5.6M shares	Q3 2024 Held for 1y 2m
5 Ocular Therapeutix OCUL	Biotechnology Healthcare	$38.0M	3.85%	+$12.3M Bought	1.87% 3.3M shares	Q4 2023 Held for 1y 11m
6 Cidara Therapeutics CDTX	Biotechnology Healthcare	$35.9M	3.64%	+$17.7M Bought	1.48% 375.0K shares	Q2 2025 Held for 5 months
7 Verastem VSTM	Biotechnology Healthcare	$35.8M	3.62%	+$26.9M Bought	6.58% 4.1M shares	Q2 2025 Held for 5 months
8 ABVX Abivax ABVX	Unknown Unknown	$35.2M	3.57%	+$35.2M New	— 415.0K shares	Q3 2025 Held for 2 months
9 Erasca, Inc. ERAS	Biotechnology Healthcare	$33.0M	3.34%	+$327.0K Bought	5.34% 15.2M shares	Q2 2024 Held for 1y 5m
10 Maze Therapeutics, Inc. Common Stock MAZE	Unknown Unknown	$31.8M	3.22%	+$16.0M Bought	2.80% 1.2M shares	Q1 2025 Held for 8 months

See all holdings

GthenH

Changes

Portfolio activity, position movements, and quarter-over-quarter changes in Logos Global Management LP's latest filing

See all changes

GthenC

Market Value

$987.5M

Prior: $731.0M

Q/Q Change

+35.09%

+$256.5M

Net Flows % of MV

-4.01%

Turnover Ratio

32.59%

New Purchases

11 stocks

$109.8M

Added To

13 stocks

+$131.2M

Sold Out Of

13 stocks

$139.9M

Reduced Holdings

13 stocks

-$140.6M

Increased Positions

Position	Shares Δ	Change
1 ABVX Abivax ABVX	New	0 → 415.0K +$35.2M
2 Amylyx Pharmaceuticals, Inc. AMLX	New	0 → 1.5M +$19.7M
3 LBRX LB Pharmaceuticals Inc Common Stock LBRX	New	0 → 1.1M +$17.8M
4 Dianthus Therapeutics DNTH	New	0 → 200.0K +$7.9M
5 Compass Therapeutics, Inc. CMPX	New	0 → 2.1M +$7.2M

Decreased Positions

Position	Shares Δ	Change
1 United Therapeutics UTHR	Sold	85.0K → 0 −$24.4M
2 Neurocrine Biosciences NBIX	Sold	150.0K → 0 −$18.9M
3 Madrigal Pharmaceuticals, Inc. MDGL	Sold	50.0K → 0 −$15.1M
4 Krystal Biotech, Inc. KRYS	Sold	100.0K → 0 −$13.7M
5 Celldex Therapeutics CLDX	Sold	600.0K → 0 −$12.2M